Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Sosei Group ( (JP:4565) ) is now available.
Nxera Pharma Co., Ltd. announced a strategic restructuring to enhance its path to profitability by concentrating on high-value programs and reducing operating expenses. The company aims to achieve significant cost savings and streamline operations, including a 15% workforce reduction, to support its ambitious 2030 vision of achieving JPY50 billion in net sales and a 30% operating profit margin. This restructuring will focus on prioritized R&D programs, particularly in obesity and metabolic disorders, while utilizing AI technology to enhance drug discovery processes.
The most recent analyst rating on (JP:4565) stock is a Hold with a Yen767.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma Co., Ltd. operates in the biopharmaceutical industry, focusing on the development of next-generation therapies for obesity, metabolic, and endocrine disorders. The company leverages its proprietary NxWave™ platform to generate medicines with a differentiated profile, emphasizing G protein-coupled receptor (GPCR) targets.
YTD Price Performance: -17.75%
Average Trading Volume: 739,316
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen78.01B
Find detailed analytics on 4565 stock on TipRanks’ Stock Analysis page.